Recently Featured

Trump Administration’s Actions Undermine Alcohol Addiction Research and Prevention Efforts

July 19, 2026
The Trump administration’s approach to alcohol-related health issues has significantly hindered research and prevention efforts, according to a recent investigation by STAT. Despite alcohol being responsible for more deaths in the U.S. than infectious diseases and opioids combined, the administration has largely ignored its risks while catering to the alcohol industry. While the Make America…

Zymeworks Agrees to Acquire Theravance Biopharma for $929 Million

July 19, 2026
Zymeworks has signed an agreement to acquire Theravance Biopharma in a cash transaction valued at approximately $929 million. This strategic move is expected to enhance Zymeworks’ portfolio, particularly in the areas of oncology and immunology, where Theravance has established a strong presence with its innovative therapeutics. The acquisition reflects a growing trend in the biopharmaceutical…

Stanford Study Identifies Dual Proteins Crucial for Skin Health

July 18, 2026
Research led by Stanford Medicine has unveiled two proteins, NEDD8 and SUMO2, that play opposing roles in the development and maintenance of healthy skin. These proteins belong to the ubiquitin-like protein family, which is integral to cellular processes. The study suggests that modulating the activity of these proteins through topical treatments could offer new avenues…

PALSONIFY Receives FDA Approval for Acromegaly Treatment

July 18, 2026
PALSONIFY, a somatostatin receptor analog, has recently been approved by the FDA for the treatment of adults suffering from acromegaly who have not adequately responded to surgical interventions or for whom surgery is not a viable option. This approval marks a significant advancement in therapeutic options for patients facing this rare endocrine disorder, characterized by…

Ongoing Cases